PTC Therapeutics, Inc. Selling, General and Administrative Expense
PTC Therapeutics, Inc. (PTCT) reported Selling, General and Administrative Expense of $80.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- PTC Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $80.63M, a 5.43% decline year-over-year.
- PTC Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $86.18M, a 6.45% increase year-over-year.
- PTC Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $96.87M, a 14.40% increase year-over-year.
- PTC Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $84.05M, a 14.42% increase year-over-year.
- PTC Therapeutics, Inc. selling, general and administrative expense for fiscal 2025 was $347.14M, a 15.36% increase from fiscal 2024.
- PTC Therapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $300.91M, a 9.51% decline from fiscal 2023.
- PTC Therapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $332.54M, a 2.01% increase from fiscal 2022.
- PTC Therapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $326.00M, a 14.08% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $80.63M 10-Q · filed 2026-07-30 | $166.81M 10-Q · filed 2026-07-30 | $263.69M derived: sum of 3 quarters · filed 2026-07-30 | $347.73M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $86.18M 10-Q · filed 2026-05-07 | $183.06M derived: sum of 2 quarters · filed 2026-05-07 | $267.10M derived: sum of 3 quarters · filed 2026-05-07 | $352.37M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $96.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $180.92M derived: sum of 2 quarters · filed 2026-02-19 | $266.18M derived: sum of 3 quarters · filed 2026-07-30 | $347.14M 10-K · filed 2026-02-19 |
| 2025-09-30 | $84.05M 10-Q · filed 2025-11-04 | $169.31M derived: sum of 2 quarters · filed 2026-07-30 | $250.27M 10-Q · filed 2025-11-04 | $334.95M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $85.26M 10-Q · filed 2026-07-30 | $166.22M 10-Q · filed 2026-07-30 | $250.91M derived: sum of 3 quarters · filed 2026-07-30 | $324.36M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $80.96M 10-Q · filed 2026-05-07 | $165.64M derived: sum of 2 quarters · filed 2026-05-07 | $239.10M derived: sum of 3 quarters · filed 2026-05-07 | $308.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $84.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $158.14M derived: sum of 2 quarters · filed 2026-02-19 | $227.64M derived: sum of 3 quarters · filed 2026-02-19 | $300.91M 10-K · filed 2026-02-19 |
| 2024-09-30 | $73.46M 10-Q · filed 2025-11-04 | $142.96M derived: sum of 2 quarters · filed 2025-11-04 | $216.23M 10-Q · filed 2025-11-04 | $292.52M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $69.50M 10-Q · filed 2025-08-07 | $142.77M 10-Q · filed 2025-08-07 | $219.06M derived: sum of 3 quarters · filed 2026-02-19 | $299.95M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $73.27M 10-Q · filed 2025-05-06 | $149.56M derived: sum of 2 quarters · filed 2026-02-19 | $230.45M derived: sum of 3 quarters · filed 2026-02-19 | $318.90M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $76.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $157.18M derived: sum of 2 quarters · filed 2026-02-19 | $245.63M derived: sum of 3 quarters · filed 2026-02-19 | $332.54M 10-K · filed 2026-02-19 |
| 2023-09-30 | $80.89M 10-Q · filed 2024-11-07 | $169.34M derived: sum of 2 quarters · filed 2024-11-07 | $256.25M 10-Q · filed 2024-11-07 | $348.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $88.45M 10-Q · filed 2024-08-08 | $175.36M 10-Q · filed 2024-08-08 | $268.08M derived: sum of 3 quarters · filed 2025-02-27 | $348.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $86.91M 10-Q · filed 2024-04-25 | $179.63M derived: sum of 2 quarters · filed 2025-02-27 | $259.75M derived: sum of 3 quarters · filed 2025-02-27 | $339.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $92.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $172.84M derived: sum of 2 quarters · filed 2025-02-27 | $252.73M derived: sum of 3 quarters · filed 2025-02-27 | $326.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $80.12M 10-Q · filed 2023-10-26 | $160.01M derived: sum of 2 quarters · filed 2023-10-26 | $233.28M 10-Q · filed 2023-10-26 | $319.83M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $79.89M 10-Q · filed 2023-08-03 | $153.16M 10-Q · filed 2023-08-03 | $239.71M derived: sum of 3 quarters · filed 2024-02-29 | $308.96M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $73.27M 10-Q · filed 2023-04-27 | $159.82M derived: sum of 2 quarters · filed 2024-02-29 | $229.07M derived: sum of 3 quarters · filed 2024-02-29 | $297.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $86.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $155.80M derived: sum of 2 quarters · filed 2024-02-29 | $224.68M derived: sum of 3 quarters · filed 2024-02-29 | $285.77M 10-K · filed 2024-02-29 |
| 2021-09-30 | $69.25M 10-Q · filed 2022-10-27 | $138.13M derived: sum of 2 quarters · filed 2022-10-27 | $199.22M 10-Q · filed 2022-10-27 | $274.68M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $68.88M 10-Q · filed 2022-08-04 | $129.97M 10-Q · filed 2022-08-04 | $205.43M derived: sum of 3 quarters · filed 2023-02-21 | $263.27M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $61.09M 10-Q · filed 2022-05-03 | $136.55M derived: sum of 2 quarters · filed 2023-02-21 | $194.39M derived: sum of 3 quarters · filed 2023-02-21 | $248.05M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $75.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $133.30M derived: sum of 2 quarters · filed 2023-02-21 | $186.96M derived: sum of 3 quarters · filed 2023-02-21 | $245.16M 10-K · filed 2023-02-21 |
| 2020-09-30 | $57.84M 10-Q · filed 2021-10-28 | $111.50M derived: sum of 2 quarters · filed 2021-10-28 | $169.71M 10-Q · filed 2021-10-28 | $233.21M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $53.66M 10-Q · filed 2021-07-29 | $111.87M 10-Q · filed 2021-07-29 | $175.37M derived: sum of 3 quarters · filed 2022-02-22 | $224.65M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $58.21M 10-Q · filed 2021-05-04 | $121.71M derived: sum of 2 quarters · filed 2022-02-22 | $170.99M derived: sum of 3 quarters · filed 2022-02-22 | $220.21M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $63.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $112.78M derived: sum of 2 quarters · filed 2022-02-22 | $162.00M derived: sum of 3 quarters · filed 2022-02-22 | $202.54M 10-K · filed 2022-02-22 |
| 2019-09-30 | $49.28M 10-Q · filed 2020-10-29 | $98.50M derived: sum of 2 quarters · filed 2020-10-29 | $139.04M 10-Q · filed 2020-10-29 | $187.71M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $49.22M 10-Q · filed 2020-08-05 | $89.76M 10-Q · filed 2020-08-05 | $138.43M derived: sum of 3 quarters · filed 2021-02-25 | $176.79M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $40.54M 10-Q · filed 2020-04-30 | $89.21M derived: sum of 2 quarters · filed 2021-02-25 | $127.58M derived: sum of 3 quarters · filed 2021-02-25 | $161.12M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $48.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $87.03M derived: sum of 2 quarters · filed 2021-02-25 | $120.58M derived: sum of 3 quarters · filed 2021-02-25 | $153.55M 10-K · filed 2021-02-25 |
| 2018-09-30 | $38.37M 10-Q · filed 2019-10-30 | $71.91M derived: sum of 2 quarters · filed 2019-10-30 | $104.88M 10-Q · filed 2019-10-30 | $140.37M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $33.55M 10-Q · filed 2019-08-06 | $66.51M 10-Q · filed 2019-08-06 | $102.00M derived: sum of 3 quarters · filed 2020-03-02 | $133.42M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $32.97M 10-Q · filed 2019-05-02 | $68.45M derived: sum of 2 quarters · filed 2020-03-02 | $99.88M derived: sum of 3 quarters · filed 2020-03-02 | $128.74M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $35.48M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $66.91M derived: sum of 2 quarters · filed 2020-03-02 | $95.77M derived: sum of 3 quarters · filed 2020-03-02 | $121.27M 10-K · filed 2020-03-02 |
| 2017-09-30 | $31.42M 10-Q · filed 2018-11-05 | $60.29M derived: sum of 2 quarters · filed 2018-11-05 | $85.79M 10-Q · filed 2018-11-05 | $109.96M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $28.87M 10-Q · filed 2018-08-07 | $54.37M 10-Q · filed 2018-08-07 | $78.54M derived: sum of 3 quarters · filed 2019-03-01 | $102.19M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $25.50M 10-Q · filed 2018-05-09 | $49.67M derived: sum of 2 quarters · filed 2019-03-01 | $73.33M derived: sum of 3 quarters · filed 2019-03-01 | $96.69M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $24.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $47.83M derived: sum of 2 quarters · filed 2019-03-01 | $71.19M derived: sum of 3 quarters · filed 2019-03-01 | $97.13M 10-K · filed 2019-03-01 |
| 2016-09-30 | $23.65M 10-Q · filed 2017-11-02 | $47.02M derived: sum of 2 quarters · filed 2017-11-02 | $72.96M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $23.37M 10-Q · filed 2017-08-09 | $49.30M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $25.94M 10-Q · filed 2017-05-08 | |||
| 2015-09-30 | $21.37M 10-Q · filed 2016-11-03 | $38.58M derived: sum of 2 quarters · filed 2016-11-03 | $56.19M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $17.21M 10-Q · filed 2016-08-04 | $34.83M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |